HomeGOVXW • NASDAQ
add
GeoVax
Nakaraang pagsara
$0.035
Sakop ng araw
$0.022 - $0.031
Sakop ng taon
$0.022 - $0.65
Market cap
13.97M USD
Average na Volume
14.23K
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 864.42K | — |
Gastos sa pagpapatakbo | 1.60M | 9.65% |
Net na kita | -8.26M | -8.83% |
Net profit margin | -955.87 | — |
Kita sa bawat share | — | — |
EBITDA | -8.32M | -8.49% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 5.51M | -14.66% |
Kabuuang asset | 8.16M | -12.14% |
Kabuuang sagutin | 3.11M | -11.72% |
Kabuuang equity | 5.05M | — |
Natitirang share | 13.84M | — |
Presyo para makapag-book | 0.07 | — |
Return on assets | -216.54% | — |
Return on capital | -307.86% | — |
Cash Flow
Net change in cash
| (USD) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -8.26M | -8.83% |
Cash mula sa mga operasyon | -7.75M | 24.56% |
Cash mula sa pag-invest | 0.00 | 100.00% |
Cash mula sa financing | 4.67M | 14.91% |
Net change in cash | -3.09M | 50.51% |
Malayang cash flow | -4.71M | 36.62% |
Tungkol
GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax uses recombinant DNA or recombinant viruses to produce virus-like particles in the person being vaccinated. Wikipedia
Itinatag
1988
Headquarters
Website
Mga Empleyado
17
